



14-16
November
2024

22ND CONVENTION OF INVESTIGATORS IN CYSTIC FIBROSIS

XXII CONVENTION D'AUTUNNO
DEI RICERCATORI IN FIBROSI CISTICA

CENTRO
CONGRESSI
CAMERA DI
COMMERCIO
VERONA

PROGRAM



*Fondazione per la Ricerca
sulla Fibrosi Cistica - ETS*
italian cystic fibrosis research foundation

Piazzale Stefani 1 | c/o Azienda Ospedaliera Universitaria Integrata | 37126 Verona
Codice fiscale 93100600233 | fondazione.ricercafc@aovr.veneto.it | Tel 045 812 3438
fibrosicisticaricerca.it

Thursday, 14 November 2024

09:30 - 10:30	Registration and poster display
10:30 - 11:20	<p>Welcome and greetings</p> <p>Matteo Marzotto (<i>President FFC Ricerca</i>) Gianna Puppo Fornaro (<i>President LIFC Lega Italiana Fibrosi Cistica</i>) Francesco Blasi (<i>President SIFC Società Italiana Fibrosi Cistica</i>) Callisto Marco Bravi (<i>Director AOUI Verona</i>) Elisa La Paglia (<i>Department of Health, Municipality of Verona</i>) Carlo Castellani (<i>Scientific director FFC Ricerca</i>) Cecilia Cascone (<i>Representative Consultation group FFC Ricerca</i>)</p>
11:20 - 11:30	<p>Not only research: education and dissemination by FFC Ricerca Carlo Castellani (<i>Scientific director FFC Ricerca</i>)</p>
11:30 - 13:05 SESSION 1	<p>FFC RICERCA STRATEGIC PROJECTS AND RESEARCH FACILITIES <i>Chair: Nicoletta Pedemonte, Carlo Castellani</i></p> <ol style="list-style-type: none"> Paola Barraja, Luis J.V. Galletta (Molecules 3.0) New generation of pharmacological modulators to rescue mutant CFTR protein (15') Anna Cereseto, Sven Even Borgos, Luis J.V. Galletta, Sheref Mansy, Serena Zacchigna (GenDel-CF) - <i>speaker Sjoerd Hak</i> Tackling gene delivery in lungs for the treatment of cystic fibrosis (15') Maria Cristina Lucanto, Cesare Braggion, Cristina Cigana, Nicoletta Pedemonte (Kaftrio in the real life) Efficacy and safety of Kaftrio in real life: an observational multicenter Italian clinical study (10') Alessandra Bragonzi (CFaCore) FFC Ricerca Research facilities: The cystic fibrosis animal core (10') Valeria Capurro (SCP) FFC Ricerca Research facilities: The primary cell cultures service (10') Roberto Buzzetti (CFDB) FFC Ricerca Research facilities: The cystic fibrosis database (10')
12:40 - 13:05	Discussion
13:05 - 14:30	Lunch
14:30 - 16:15 SESSION 2	<p>ORPHAN MUTATIONS AND NEW THERAPEUTIC APPROACHES <i>Chair: Nicoletta Pedemonte, Maria Cristina Lucanto</i></p> <ol style="list-style-type: none"> Massimo Aureli, Anna Tamanini (FFC#1/2022) A lipid-based therapeutic approach to rescue CFTR with orphan mutations and implications in bacterial infections in cystic fibrosis (10') Emilio Hirsch (FFC#3/2022) Rescuing rare CFTR mutants with a PI3Kγ mimetic peptide (20') Giulia Maule (GMSG#1/2022) Development of CRISPR-Cas delivery system for genome editing applications in cystic fibrosis (10') Riccardo Percudani, Gianfranco Pasut, Rosaria Casciaro (FFC#14/2022) Actin-resistant acidic DNase for the treatment of CF pulmonary symptoms (20') Maria Luisa Mangoni, Arianna Venturini, Mattia Mori (FFC#4/2022) Esculentin-derived peptides as novel therapeutic agents with antimicrobial and CFTR potentiator activities to address cystic fibrosis lung disease (20')
15:50 - 16:15	Discussion

16:15 - 16:40
SESSION 3

FLASH PRESENTATION 1: 2024 NEW PROJECTS

Chair: Ermanno Rizzi

12. **Giovanni Marzaro, Tamas Hegedus, Gergely L. Lukacs** (FFC#1/2024)
Development of new potentiators active on (ultra)rare mutants of CFTR (3')
13. **Mauro Salvi** (FFC#3/2024)
Promoting correct folding to enhance F508del-CFTR rescue induced by correctors (3')
14. **Giovanni Bertoni, Silvia Ferrara** (FFC#5/2024)
Targeting bacterial small RNA to develop non-traditional therapeutic options against *Pseudomonas aeruginosa* (3')
15. **Sandra Gemma, Arianna Pompilio** (FFC#7/2024)
Targeting quorum sensing to fight *Pseudomonas aeruginosa* infections (3')
16. **Santiago Ramòn-García** (FFC#9/2024) - *speaker Lara Muñoz Muñoz*
Understanding the contribution of Kaftrio to antimicrobial therapies against nontuberculous mycobacteria in cystic fibrosis (3')
17. **Antonio Recchiuti** (FFC#13/2024)
Unraveling proresolving effects of CFTR modulators on lung inflammation and infection (3')
18. **Martina Rossitto, Marco Artini** (FFC#15/2024)
Analysis of the evolution of virulence factors and antimicrobial resistance of *Pseudomonas aeruginosa* in people with cystic fibrosis (3')

16:40 - 18:00

Coffee Break, Poster session and Q&A

18:00 - 18:30
KEYNOTE
SPEECH

How clinical and *in vitro* data can synergize to facilitate access to modulators in people with cystic fibrosis and orphan mutations

Pierre-Régis Burgel (30')

French National Cystic Fibrosis Reference Center, Université Paris-Cité, Paris, France

08:30 - 09:50
SESSION 4

EXPERIMENTAL MODELS AND CFTR BASIC DEFECTS

Chair: Valeria Capurro, Giuseppe Magazzù

19. **Roberto Plebani** (GMSG#1/2023)
Developing a new respiratory 3D model as an innovative strategy to study the inflammation pathology in cystic fibrosis (10')
20. **Marco Cafora** (GMRF#1/2023)
Ex vivo pig lung as a new model to study the efficacy of phage therapy against *Pseudomonas aeruginosa* infection in cystic fibrosis (10')
21. **Carlos M. Farinha, Valeria Tomati** (FFC#2/2023)
Exploring the cellular pathways to promote rescue of mutant CFTR protein in cystic fibrosis (10')
22. **Alessandra Bragonzi, Federica Ungaro, Valeria Daccò** (FFC#5/2023)
Beyond the lung: the gut's role in the pathology of cystic fibrosis (10')
23. **Luis J. V. Galiotta** (FFC#9/2022)
Effect of inflammatory stimuli on airway epithelium ion transport in cystic fibrosis (20')

9:30 - 9:50

Discussion

9:50 - 10:55
SESSION 5

BIOLOGICAL EFFECTS OF KAFTRIO

Chair: Luis J.V. Galiotta, Giuseppe Magazzù

24. **Andrea Armirotti, Rosaria Bassi** (FFC#1/2023)
Investigation of Kaftrio secondary effects on sphingolipid synthesis (20')
25. **Renata Bocciardi** (FFC#3/2023)
Understanding the mechanisms behind the variable efficacy of CFTR modulators on the N1303K mutation on human primary nasal epithelial cells (10')
26. **Cristina Cigana, Daniela Girelli, Ersilia Vita Fiscarelli** (FFC#16/2021)
Linking elexacaftor/tezacaftor/ivacaftor to infections in cystic fibrosis lung disease (20')

10:40 - 10:55

Discussion

10:55 - 11:20

Coffee Break

11:20 - 12:25
SESSION 6

PHAGE THERAPY

Chair: Alessandra Bragonzi, Carlo Castellani

27. **Anna Silvia Pistocchi** (FFC#12/2022)
Evaluation of phage interactions with host immune system in models of cystic fibrosis: one step toward phage therapy application (20')
28. **Federica Briani** (FFC#16/2023)
Facing resistance to therapeutic phages observed in *Pseudomonas aeruginosa* isolates from people with cystic fibrosis (10')
29. **Loris Rizzello, Giulia Degiacomi** (FFC#11/2023) - *speaker Anna Griego*
Resolving *Mycobacterium abscessus* infections with a phages-inspired therapy (20')

12:10 - 12:25

Discussion

12:25 - 12:50
SESSION 7

FLASH PRESENTATION 2: 2024 NEW PROJECTS

Chair: *Ermanno Rizzi*

30. **Lucilla Nobbio, Andrea Armirotti** (FFC#2/2024)
Investigating the safety of elexacaftor/tezacaftor/ivacaftor (ETI) exposure during pregnancy and early development (3')
31. **Onofrio Laselva, Valeria Capurro, Enza Montemitro** (FFC#4/2024)
A personalized repurposing approach based on anti-inflammatory/antioxidant treatment to increase the efficacy of CFTR modulators (3')
32. **Mariagrazia Di Luca, Laura Rindi, Andrea Moscatelli** (FFC#6/2024)
Development of phage therapy for treating *Mycobacterium abscessus* lung infections in people with cystic fibrosis (3')
33. **Annalisa Guaragna, Eliana De Gregorio** (FFC#8/2024)
A combined therapy against *Pseudomonas aeruginosa-Staphylococcus aureus* co-infections in cystic fibrosis (3')
34. **Stefano Sabatini, Laura Rindi** (FFC#10/2024)
Phenotypic medicinal chemistry approaches to identify new anti-*Mycobacterium abscessus* agents (3')
35. **Alberto Battezzati, Federico Alghisi, Stefano Costa** (FFC#14/2024)
Long-term clinical outcomes of insulin secretory defects and effects of CFTR modulators (3')
36. **Daniela Guidone** (GMR#1/2024)
Airway surface as a battleground against bacteria (3')
37. **Michele Genovese** (GMSG#1/2024)
Alternative therapeutic target to restore the mucociliary clearance in CF (3')

12:50

Group photo at Auditorium

13:10 - 15:10

Lunch, Poster session and Q&A

15:10 - 16:40
SESSION 8

UNDERSTANDING INFLAMMATION

Chair: *Giulio Cabrini, Natalia Cirilli*

38. **Domenico Mattoscio** (FFC#11/2022, FFC#12/2024)
Targeting platelet activation with pro-resolving mediators: an innovative strategy to dampen lung inflammation in cystic fibrosis (23')
39. **Mario Romano, Mauro Perretti** (FFC#15/2023)
Melanocortins to control cystic fibrosis airway inflammation (10')
40. **Moira Paroni, Clelia Peano** (FFC#14/2023)
Identification of molecular mechanisms which underpin the activation of pathogenic pulmonary Th1/17 cells in cystic fibrosis (10')
41. **Ilaria Lampronti, Adriana Chilin** (FFC#10/2022, FFC#11/2024)
Towards the development of GY-971a as anti-inflammatory drug in cystic fibrosis (23')

16:16 - 16:40

Discussion

16:40 - 17:05

Coffee Break

17:05 - 17:35
KEYNOTE
SPEECH

Inflammation research priorities in the changing scenario of cystic fibrosis

Marcus A. Mall (30')

Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité – Universitätsmedizin Berlin, Germany

20:00

SOCIAL DINNER

at Palazzo Verità Poeta - Vicolo San Silvestro 6, Verona

9:30 - 11:25
SESSION 9

NEW STRATEGIES AGAINST PSEUDOMONAS AND ASPERGILLUS

Chair: Paola Bruni, Sonia Volpi

42. **Barbara Citterio, Massimiliano Lucidi** (FFC#7/2023) - *speaker Gianmarco Mangiaterra*
Evaluation of cefiderocol activity against *Pseudomonas aeruginosa* in cystic fibrosis lung infections (10')
43. **Giordano Rampioni** (FFC#10/2023)
Drug repurposing to inhibit *Pseudomonas aeruginosa* adaptation to the CF lung environment (20')
44. **Silvia Buroni, Antonio Coluccia** (FFC#6/2023)
Using a Virtual Screening approach to find new drugs against *Pseudomonas aeruginosa* and *Staphylococcus aureus* (10')
45. **Marco Sette, Mattia Falconi, Marco Rinaldo Oggioni** (FFC#13/2023)
Building simple molecules containing regions of *Pseudomonas aeruginosa* to stimulate the immune system against this pathogen (10')
46. **Eugenio Notomista, Ivana D'Angelo** (FFC#8/2023)
Inhalable nanoparticles delivering peptidomimetic/antibiotic combinations for local treatment of CF lung infections (10')
47. **Andrea Battistoni, Luigi Scipione** (FFC#4/2023)
A Trojan horse strategy to improve the treatment of *Pseudomonas aeruginosa* lung infections (20')
48. **Teresa Zelante** (FFC#15/2022)
Study on anti-fungal immunoglobulins, as a potential diagnostic biomarker and therapeutic values for allergic bronchopulmonary aspergillosis in children with cystic fibrosis (10')

11:00 - 11:25 Discussion

11:25 - 11:55 Coffee Break

11:55 - 13:25
SESSION 10

FIGHTING MYCOBACTERIA INFECTIONS

Chair: Alessandra Bragonzi, Natalia Cirilli

49. **Nicola Ivan Lorè, Lisa Cariani** (FFC#7/2022)
Genomic and phenotypic characterization of *Mycobacterium abscessus* and detection of host biomarkers to define mycobacterial infection in cystic fibrosis (10')
50. **Laurent Robert Chiarelli, Fiorella Meneghetti, Sonia Covaceuszach** (FFC#5/2022)
Nontuberculous mycobacteria in cystic fibrosis: scouting molecules against *Mycobacterium abscessus* iron acquisition pathways (20')
51. **Maurizio Fraziano, Daniela Maria Cirillo** (FFC#13/2022)
Fighting *Mycobacterium abscessus* infections by a novel combination therapy (20')
52. **Edoardo Scarpa, Daniela Maria Cirillo** (FFC#12/2023)
Fostering pathogen host-mediated clearance to neutralize *Mycobacterium abscessus* infection (10')
53. **Maria Rosalia Pasca, Fabio Saliu, Riccardo Manganeli** (FFC#9/2023)
Evaluation of the efficacy of the "VOMG" new antibiotic against *Mycobacterium abscessus* (10')

Tamberi ha
affrontato nella
sua carriera tante
difficoltà, non
arrendendosi mai.

E noi, con lui al
nostro fianco,
facciamo lo
stesso.



Emma, ragazza con la fibrosi cistica e Gianmarco Tamberi, campione olimpico di salto in alto



*Fondazione per la Ricerca
sulla Fibrosi Cistica - ETS*
fibrosicisticaricerca.it

**Sostieni la ricerca per i malati
ancora senza cura.**

**A NATALE SCEGLI I DONI
SOLIDALI FFC RICERCA**
su fibrosicisticaricerca.it